Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

87.61 -2.81 (-3.10%)
Streaming Delayed Price Updated: 10:22 AM EDT, May 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Dianthus Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 ↗
This clinical-stage biotech focused on monoclonal antibody therapies reported a notable insider sale in its latest SEC filing. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics CFO Sells $9.5 Million in Stock ↗
This biotech firm developing antibody therapies for rare diseases disclosed a significant insider sale amid rapid share price gains. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions. 
Via The Motley Fool
News headline image
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal... 
Via Finterra
Topics Economy
News headline image
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗
Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of... 
Via Stocktwits
Gapping stocks in Monday's session ↗
Via Chartmill
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026
The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run ↗
This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC disclosure. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics to Participate in Four Investor Conferences During November
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
General Motors To Rally More Than 24%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Dianthus Therapeutics Highlights Claseprubart Data Presentations Planned for 2025 AANEM Annual Meeting
Positive results from Phase 2 MaGic trial including additional analyses, and new preclinical data highlighting potential benefits of upstream inhibition, to be presented for claseprubart in generalized... 
From Dianthus Therapeutics, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks Showing Strength With Big Spikes In Momentum Scores ↗
A handful of biotech stocks are showing renewed strength, with big spikes in their Benzinga Edge Ranking's Momentum scores. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.